Puberty blockers have been prescribed to cisgender children for decades, primarily for precocious puberty, with the same bone density and fertility considerations that apply in trans care. The restrictions placed on their use in trans young people are not driven by new safety evidence but by political pressure applied to one group and not the other.
What are puberty blockers, and how long have they been in use?
Puberty blockers are medications that temporarily pause the body's production of sex hormones, stopping the physical changes of puberty from progressing. The most commonly used belong to a class called GnRH analogues (gonadotrophin-releasing hormone analogues), which work by suppressing the signals from the brain that trigger hormone release. When the medication is stopped, puberty resumes.
These medications have been in clinical use since the 1980s. They were developed and licensed primarily for the treatment of precocious puberty, a condition in which puberty begins far too early, sometimes in children as young as two or three years old. Allowing precocious puberty to proceed untreated carries real harms: premature bone fusion that results in shorter adult stature, significant psychological distress, and the social and emotional difficulty of a young child experiencing adult physical changes long before their peers. Pausing that process with a GnRH analogue is well-established, uncontroversial medicine.
What other conditions are they used for in cisgender children?
Beyond precocious puberty, puberty blockers are used in a number of other clinical contexts where suppressing sex hormone production is medically indicated. They are used in the treatment of certain hormone-sensitive cancers, in managing endometriosis, and in conditions involving abnormal uterine bleeding. They are also sometimes used in children with conditions such as congenital adrenal hyperplasia, where the hormonal picture is complex and carefully managed over time.
In all of these contexts, the medications being prescribed are the same ones used in gender-affirming care for trans young people. The doses, the mechanisms, and the monitoring protocols are comparable. The clinical teams managing these children are aware of the considerations around bone density and long-term fertility, and they weigh those considerations against the benefits of treatment, exactly as clinicians in gender-affirming care do.
What are the actual bone density and fertility considerations?
The concerns are often discussed in the context of trans care as though they are unique to it, and they are not.
Bone density: sex hormones play a role in bone mineralisation during puberty. Pausing puberty with a GnRH analogue means that some of the bone density accumulation that would ordinarily happen during that window is delayed. Research in children treated for precocious puberty shows that bone density generally catches up once treatment stops and puberty resumes or, in the case of trans young people who go on to hormones, once cross-sex hormones are introduced and bone mineralisation continues on that pathway. The concern is real and is part of good monitoring in all clinical contexts, trans or otherwise. It does not represent a unique or unmanageable risk in trans care.
Fertility: a child who remains on puberty blockers throughout what would have been their natal puberty, and then transitions to cross-sex hormones, will not have produced mature eggs or sperm. If fertility preservation is something the young person or their family wants to consider, that conversation needs to happen early, before treatment begins, and options such as sperm banking or egg preservation may be available depending on age and stage. This is a real and important consideration. It is also a consideration that arises in other paediatric contexts: children receiving chemotherapy face fertility impacts, sometimes irreversibly, and that is managed through counselling and, where possible, preservation. The approach is the same; the outcry has not been the same.
So why are the restrictions applied only to trans young people?
This is the question that matters, and the answer is not a clinical one.
The UK government's ban on the private prescription of puberty blockers to trans young people, which came into force following pressure generated in large part by the Cass Review, was not accompanied by any equivalent restriction on the prescription of the same medications for precocious puberty or any other cisgender indication. The medications did not change. The evidence base did not change. The known considerations around bone density and fertility did not become more serious or less manageable overnight. What changed was the political will to restrict access for one specific group of children.
The Cass Review, which drove much of this policy shift in the UK and influenced policy decisions in other countries, has been widely discredited internationally. Researchers, clinicians, and public health academics in multiple countries have published detailed rebuttals of its methodology and its conclusions. The major international bodies in this field, including WPATH, the Endocrine Society, the American Academy of Pediatrics, and the American Academy of Child and Adolescent Psychiatry, continue to support access to puberty blockers as part of gender-affirming care for appropriate candidates. The AACAP reaffirmed that position explicitly in 2025, directly in response to political pressure in the United States.
The inconsistency is not subtle. If the bone density concern were driving policy, we would expect to see the same restrictions applied to cisgender children receiving the same medications for precocious puberty. We do not. If the fertility concern were the issue, we would expect the same level of regulatory scrutiny applied to the fertility impacts of paediatric chemotherapy. We do not see that either. What we see is targeted restriction of a medication when it is used for one group of children, and unremarked routine use of the identical medication in everyone else.
What does this mean for the children it affects?
Many trans young people and their families have told me what it felt like to have treatment withdrawn or made inaccessible not because their circumstances changed, not because new evidence emerged about their specific case, but because a policy decision closed the door. The puberty they had been pausing resumed. The changes they had been hoping to avoid arrived. The distress that the treatment had been managing returned, sometimes acutely.
Delay in this context is not a neutral holding position. Unwanted puberty changes can cause lasting distress, and some of those changes, the deepening of a voice, the development of facial bone structure, breast growth, are not reversible. The harm of withholding care is real and documented, even when it is less visible in a policy document than the risks of providing it.
Why does the framing of "caution" apply to only one group?
One of the things that has struck me most, over many years of working in and around this field, is how the language of caution is applied asymmetrically. "We need more evidence" is a phrase that appears constantly in discussions about trans healthcare, rarely in discussions about other paediatric uses of the same medications. "Long-term effects are unknown" is raised as a reason for restriction in trans care while the same phrase never grounds a moratorium on the use of GnRH analogues in precocious puberty, despite those long-term effects being similarly monitored and similarly understood.
Caution is not a neutral scientific value when it is applied selectively. Applied only to one group of children, it functions as a justification for exclusion rather than a guide to good medicine. Good medicine asks what the evidence says, what the individual child's situation is, what the risks of treatment are, and what the risks of withholding treatment are. It asks those questions consistently, regardless of who the child is.
What should a parent or young person take from this?
If you are a parent trying to make sense of why access has become so restricted when the medication itself has a long clinical history, you are asking exactly the right question. The restriction is political, not clinical, and the international medical consensus remains that, for appropriate candidates, puberty blockers are a legitimate and beneficial part of gender-affirming care.
If you are a young person who wanted access to this treatment and has been told it is unavailable, that is a genuine harm that has been done to you, and it is not your fault, and it is not because the medicine was wrong for you. The pathway to getting support has been deliberately narrowed, but it has not been closed entirely, and it is worth pursuing with a doctor who understands the full picture.
If you are a clinician or a policy maker looking at this from the outside, the comparison I have laid out here is not rhetorical point-scoring. It is a genuine inconsistency in how evidence and risk are being applied, and it deserves a straight answer rather than a political one.
Comments